BALIAKAS, P., A. HADZIDIMITRIOU, L. A. SUTTON, E. MINGA, A. AGATHANGELIDIS, M. NICHELATTI, A. TSANOUSA, L. SCARFÓ, Z. DAVIS, X.J. YAN, T. SHANAFELT, Karla PLEVOVÁ, Y. SANDBERG, F.J. VOJDEMAN, M. BOUDJOGRA, T. TZENOU, M. CHATZOULI, C.C. CHU, S. VERONESE, A. GARDINER, L. MANSOURI, K.E. SMEDBY, L.B. PEDERSEN, K. VAN LOM, V. GIUDECELLI, Hana SKUHROVÁ FRANCOVÁ, F. NGUYEN-KHAC, P. PANAGIOTIDIS, G. JULIUSSON, L. ANGELIS, A. ANAGNOSTOPOULOS, M.P. LEFRANC, M. FACCO, L. TRENTIN, M. CATHERWOOD, M. MONTILLO, C.H. GEISLER, A.W. LANGERAK, Šárka POSPÍŠILOVÁ, N. CHIORAZZI, D. OSCIER, D.F. JELINEK, Nikos DARZENTAS, C. BELESSI, F. DAVI, R. ROSENQUIST, P. GHIA and K. STAMATOPOULOS. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: A retrospective multicentre study. The Lancet. Haematology. England, 2014, vol. 1, No 2, p. "e74"-"e84", 11 pp. ISSN 2352-3026. Available from: https://dx.doi.org/10.1016/S2352-3026(14)00005-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: A retrospective multicentre study
Authors BALIAKAS, P. (300 Greece), A. HADZIDIMITRIOU (300 Greece), L. A. SUTTON (752 Sweden), E. MINGA (300 Greece), A. AGATHANGELIDIS (380 Italy), M. NICHELATTI (380 Italy), A. TSANOUSA (300 Greece), L. SCARFÓ (380 Italy), Z. DAVIS (826 United Kingdom of Great Britain and Northern Ireland), X.J. YAN (840 United States of America), T. SHANAFELT (826 United Kingdom of Great Britain and Northern Ireland), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Y. SANDBERG (840 United States of America), F.J. VOJDEMAN (528 Netherlands), M. BOUDJOGRA (528 Netherlands), T. TZENOU (300 Greece), M. CHATZOULI (300 Greece), C.C. CHU (826 United Kingdom of Great Britain and Northern Ireland), S. VERONESE (380 Italy), A. GARDINER (826 United Kingdom of Great Britain and Northern Ireland), L. MANSOURI (752 Sweden), K.E. SMEDBY (752 Sweden), L.B. PEDERSEN (528 Netherlands), K. VAN LOM (528 Netherlands), V. GIUDECELLI (250 France), Hana SKUHROVÁ FRANCOVÁ (203 Czech Republic, belonging to the institution), F. NGUYEN-KHAC (250 France), P. PANAGIOTIDIS (300 Greece), G. JULIUSSON (752 Sweden), L. ANGELIS (300 Greece), A. ANAGNOSTOPOULOS (300 Greece), M.P. LEFRANC (250 France), M. FACCO (380 Italy), L. TRENTIN (380 Italy), M. CATHERWOOD (826 United Kingdom of Great Britain and Northern Ireland), M. MONTILLO (380 Italy), C.H. GEISLER (208 Denmark), A.W. LANGERAK (840 United States of America), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), N. CHIORAZZI (840 United States of America), D. OSCIER (826 United Kingdom of Great Britain and Northern Ireland), D.F. JELINEK (840 United States of America), Nikos DARZENTAS (300 Greece, belonging to the institution), C. BELESSI (752 Sweden), F. DAVI (300 Greece), R. ROSENQUIST (752 Sweden), P. GHIA (380 Italy) and K. STAMATOPOULOS (300 Greece).
Edition The Lancet. Haematology, England, 2014, 2352-3026.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14740/14:00079243
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/S2352-3026(14)00005-2
UT WoS 000362070200008
Keywords in English B lymphocyte receptor; CD38 antigen; adolescent; adult; aged; amino acid composition; antigen expression;
Tags kontrola MP, MP, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 29/3/2019 14:01.
Abstract
Background: About 30% of cases of chronic lymphocytic leukaemia (CLL) carry quasi-identical B-cell receptorimmunoglobulins and can be assigned to distinct stereotyped subsets. Although preliminary evidence suggeststhat B-cell receptor immunoglobulin stereotypy is relevant from a clinical viewpoint, this aspect has never beenexplored in a systematic manner or in a cohort of adequate size that would enable clinical conclusions to be drawn.Methods: For this retrospective, multicentre study, we analysed 8593 patients with CLL for whom immunogeneticdata were available. These patients were followed up in 15 academic institutions throughout Europe (in CzechRepublic, Denmark, France, Greece, Italy, Netherlands, Sweden, and the UK) and the USA, and data were collectedbetween June 1, 2012, and June 7, 2013. We retrospectively assessed the clinical implications of CLL B-cell receptorimmunoglobulin stereotypy, with a particular focus on 14 major stereotyped subsets comprising cases expressingunmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain variable genes. The primary outcome ofour analysis was time to fi rst treatment, defi ned as the time between diagnosis and date of fi rst treatment.Findings: 2878 patients were assigned to a stereotyped subset, of which 1122 patients belonged to one of 14 majorsubsets. Stereotyped subsets showed signifi cant diff erences in terms of age, sex, disease burden at diagnosis,CD38 expression, and cytogenetic aberrations of prognostic signifi cance. Patients within a specifi c subset generallyfollowed the same clinical course, whereas patients in diff erent stereotyped subsets-despite having the sameimmunoglobulin heavy variable gene and displaying similar immunoglobulin mutational status-showedsubstantially diff erent times to fi rst treatment. By integrating B-cell receptor immunoglobulin stereotypy (forsubsets 1, 2, and 4) into the well established Döhner cytogenetic prognostic model, we showed these, whichcollectively account for around 7% of all cases of CLL and represent both U-CLL and M-CLL, constituted separateclinical entities, ranging from very indolent (subset 4) to aggressive disease (subsets 1 and 2).Interpretation: The molecular classifi cation of chronic lymphocytic leukaemia based on B-cell receptorimmunoglobulin stereotypy improves the Döhner hierarchical model and refi nes prognostication beyondimmunoglobulin mutational status, with potential implications for clinical decision making, especially withinprospective clinical trials.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
EE2.3.20.0045, research and development projectName: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
PrintDisplayed: 30/7/2024 03:30